colposcopy News
-
QIAsure Methylation Test can decrease clinically non relevant colposcopy referrals of hpv positive women with asc-us/ lsil cytology
British Journal of Cancer; https://doi.org/10.1038/s41416-021-01614-4 Primary HPV screening has doubled the number of colposcopy referrals because of direct referral of HPV-positive women with ASC-US/ LSIL cytology. This study evaluated the CIN3+ risks and colposcopy referrals by QIAsure Methylation Test analysis HPV16/18 genotyping HPV16/18/31/33/45 genotyping in HPV-positive women ...
-
DYSIS Awarded 2021 New Product Innovation Award by Frost & Sullivan
Frost & Sullivan is a global company that has been guiding their clients through transformational growth for more than 50 years. Through their independent research and analysis, Frost & Sullivan recognizes companies at the forefront of innovation and growth in their respective industries. With that, DYSIS has been awarded with the 2021 Frost & Sullivan New Product Innovation Award ...
-
The Netherlands started QIAsure Methylation Test implementation trial for triage of HPV positively screened women
With the introduction of HPV based screening in 2017 the Dutch cervical cancer screening program underwent an important improvement. More women at risk are being discovered due to the higher sensitivity of HPV assays compared to the old cytology based test program, but as a consequence the number of referrals after cytology based triage of HPV positive women has increased 3 times. The ...
-
Guided Therapeutics Turkish Distributor Doubles Order for LuViva Advanced Cervical Scan Single-Use Disposables for Turkish Ministry of Health
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that its Turkish distributor, ITEM Medical Technologies, has received an increased order for disposable Cervical Guides from the Turkish Ministry of Health (MOH). The order has more than doubled to 1.1 million disposable Cervical Guides from a ...
-
Guided Therapeutics Ships First Four LuViva Advanced Cervical Scans for $14 million Turkish Ministry of Health Order
Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has shipped the first four LuViva® Advance Cervical Scan units to its Turkish distributor for its order with the Turkish Ministry of Health (MOH). In total, the company plans to ship 25 LuViva units and 40,000 disposable Cervical ...
-
Guided Therapeutics and U.S. FDA Agree on Meeting Date to Plan Path Forward for LuViva Advanced Cervical Scan Premarket Approval Application
Guided Therapeutics, Inc. (OTCQB:GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today it will meet with the U.S. Food and Drug Administration (FDA) November 6, 2015, to review the company’s plan to submit an approvable application for the LuViva® Advanced Cervical Scan. The LuViva is designed to detect cervical ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you